Overview
- The WAYFINDER study followed roughly 298 adults with severe, uncontrolled asthma across 11 countries receiving tezepelumab every four weeks for a year.
- After 12 months, more than half discontinued daily oral corticosteroids and nearly 90% reduced to a low maintenance dose without loss of asthma control.
- Participants recorded significant gains in symptoms, lung function and quality of life, with improvements evident within two weeks and sustained throughout the study.
- Two-thirds of patients experienced no asthma attacks during the trial period, according to results published in The Lancet Respiratory Medicine and presented at the BTS Winter Meeting.
- Investigators reported adverse events in about 9% of participants with unclear causality; the AstraZeneca-funded study builds on NICE’s 2023 approval of tezepelumab as an add-on therapy, raising access, cost and long-term safety considerations.